Form 6-K TRINITY BIOTECH PLC For: Aug 14

On August 14, 2026, the Company announced that the Company and certain of its subsidiaries entered into an amendment to the credit agreement governing the companies' term loan facility with Perceptive Credit Holdings III, L.P. on August 12, 2026. The amendment provides for a total investment of approximately $7.0 million, comprising approximately $2.5 million of new debt funding and approximately $4.5 million of capitalized interest.

The Company also announced that on August 7, 2026, it received confirmation that the Company had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1).

As of August 13, 2026, the Company had 487,879,340 ordinary shares outstanding (excluding Treasury Shares). The Company's American Depositary Shares ("ADSs") are listed on Nasdaq, and each ADS represents 600 ordinary shares.

Copies of the press release and the amendment to the credit agreement are filed herewith as Exhibits 99.1 and 99.2.

EXHIBIT INDEX

Exhibit Description

99.1 Trinity Biotech Secures Additional $7.0 Million Investment from Perceptive Advisors and Regains Compliance with Nasdaq Minimum Bid Price Requirement

99.2 Limited Waiver and Fourth Amendment To Sixth Amended And Restated Credit Agreement and Guaranty, dated as of August 12, 2026, by and among Trinity Biotech, Inc., Clark Laboratories, Inc., Biopool U.S., Inc., Primus Corporation, Mardx Diagnostics, Inc. and Immco Diagnostics, Inc. Trinity Biotech PLC and certain of its Subsidiaries as guarantors and Perceptive Credit Holdings III, LP.